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32.5% oncology, 17.5% auto-immune, 15% cardiovascular, 10% neurology/mental 
health, 5% infectious, 5% diabetes, and 15% other. Modeling techniques included 
discrete event simulation (12%), individual state-transition (15%) and most com-
monly state transition with tracking states. In most cases treatment sequencing 
was modeled to reflect clinical practice or clinical trial design. Other reasons 
included assessing where in a treatment sequence the new treatment belongs 
or evaluating the addition of more efficacious treatment options to the current 
treatment sequence. Efficacy inputs were generally based on trials that consid-
ered a single intervention and not a treatment sequence. Efficacy was commonly 
assumed to be the same regardless of line of therapy. Disease-related costs and 
utilities were mostly determined by disease status or its related events, and only 
seldomly by line of therapy. ConClusions: Capturing treatment sequences in 
economic models is important for informing reimbursement, policy and clini-
cal decisions. Key considerations for determining how to best model sequences 
include: the number of treatment options, patient heterogeneity, key outcome 
events and event risk (time-varying or constant). A key challenge to model treat-
ment sequences is the scarcity of the clinical data as clinical trials do not com-
monly study sequences.
PRM95
Budget IMPact analysIs of ceReBRolysIn In the tReatMent of acute 
IscheMIc stRoke of ModeRate and seveRe degRees of seveRIty In the 
RussIan fedeRatIon
Kulikov A, Abdrashitova G
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To conduct budget impact analysis of neurotrophic and neuropro-
tective drug cerebrolysin with standard therapy compared to standard therapy 
only of ischemic stroke of moderate and severe degrees of severity according to 
the Russian healthcare system. Methods: The one year budget impact analy-
sis was conducted. We used the pharmacoeconomic analysis method – budget 
impact analysis and analysis of the direct and indirect costs. For reference, 
we accepted the exchange rate was 1 EUR = 60,64 RUB. Results: Direct costs 
include the cost of pharmacotherapy cerebrolysin, the cost of medical emergen-
cies, inpatient and outpatient - polyclinic medical care, as well as the cost of 
early neurorehabilitation, and indirect costs - the loss of gross domestic product 
as a result of disability and death, payments for sick leave and disability cost. 
As a result, the overall costs of standard treatment with cerebrolysin totaled 
378 278 RUB (6238 EUR); while the cost to standard therapy was 457 981 RUB 
(7552 EUR). Reducing the direct and indirect costs was obtained in the treatment 
group of cerebrolysin, because of lower mortality and reduce days of hospital 
stay compared with the standard therapy. ConClusions: The results of budget 
impact analysis showed that the inclusion of cerebrolysin in standard therapy of 
ischemic stroke of moderate and severe degrees of severity can reduce the over-
all cost of the Russian health care system at 79 703 RUB (1314 EUR) per patient 
per year.
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a coMPaRIson of thRee suRvIval Models to estIMate the  
cost-effectIveness of canceR IMMunotheRaPy In the tReatMent  
of advanced MelanoMa
Bohensky M1, Gorelik A2, Kim H3, Liew D1
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objeCtives: To compare methods for extrapolating survival curves for previ-
ously-untreated patients receiving nivolumab versus ipilimumab for BRAF wild-
type advanced melanoma (AM, comprising unresectable Stage III and/or Stage IV 
metastatic melanoma). Methods: Patient-level data from 203 patients with AM 
receiving nivolumab in a phase III study (nivolumab versus dacarbazine) were used 
to estimate hazards of progression and death. Of these, 56.2% (n= 114) progressed 
and 23.2% (n= 47) died during the study period. Weibull, log-logistic and a Weibull 
mixture cure model (MCM) were fitted to extrapolate trial data for overall survival 
(OS) and progression-free survival (PFS) up to a 10 year time horizon. To estimate 
transition probabilities for subjects receiving ipilimumab, hazard ratios were cal-
culated by indirect comparison of nivolumab versus ipilimumab and applied to 
underlying survival distributions. Models were evaluated graphically, using Akaike’s 
Information Criterion (AIC) and naive comparison of the extrapolated ipilimumab 
survival functions with published long-term survival data. Results: AIC scores for 
the Weibull, log-logistic and MCM were 336.47, 335.30 and 776.20 for OS, respectively. 
The equivalent AIC scores for PFS were 511.39, 479.38 and 1421.63. The estimated 
3-year survival rate of patients receiving ipilimumab was 2.8%, 15.1% and 55.8% 
and 14.9%, 40.2% and 87.2% for patients receiving nivolumab using the Weibull, log-
logistic and MCM, respectively. This compares with published data showing approxi-
mately 21% (95% CI: 17-24%) of AM patients receiving ipilimumab (3 mg/kg) survive 
three years. Due to the short follow-up period for this study, the MCM introduced 
the greatest potential for error. ConClusions: The log-logistic model provided 
the closest approximation to real-world ipilimumab data. The choice of parametric 
model exerts a large effect on predicted effectiveness and cost-effectiveness of 
new therapies and needs justification. Different models should be considered in 
sensitivity analyses to estimate their impact on ICERs.
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econoMIc and clInIcal IMPact of secondhand sMokIng In koRea
Lee J, Lee Y, Bae S
Ewha Womans University, Seoul, South Korea
bACkgRound: The health consequences attributed to cigarette smoking and sec-
ondhand smoke exposure have been studied in many countries. Nevertheless, the 
economic burden of smoking, especially focusing on secondhand smoke is rarely 
dealt with. objeCtives: To examine economic and health outcomes of secondhand 
smoking in Korea Methods: We reviewed previous studies which demonstrated the 
states (preclinical, MCI, mild, moderate, or severe AD). Patients’ rate of progres-
sion through the health states was based on a weighted average of rates among 
‘slow’ and ‘fast’ progressing patients (derived from the AD neuroimaging initia-
tive). Each state has unique utility and expenditure impacts. This lifetime horizon 
model tracks AD progression, life years, quality-adjusted life years, and expendi-
ture. ConClusions: This new framework provides a relatively simple and flexible 
way for users to simulate long-term AD and MCI health outcomes and assess the 
comparative effectiveness of strategies using a common trial endpoint.
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a coMPaRIson of dIscRete event sIMulatIon (des) veRsus MaRkov 
Models WIth a PRactIcal aPPlIcatIon to huMan-IMMunodefIcIency 
vIRus (hIv)
Gillies H
Abacus International, Bicester, UK
objeCtives: When conducting an economic evaluation, it is important to select an 
appropriate model type and provide a justification. Many analyses utilise Markov 
models but these are associated with a number of limitations. Discrete Event 
Simulation (DES) models, in which events are estimated using discrete time inter-
vals rather than regular cycles and patients are simulated individually rather than 
as a cohort, can overcome many of the Markovian limitations. The aim of this study 
was to assess the advantages and disadvantages of DES and Markov models; utilis-
ing an application to HIV. Methods: A systematic literature review was conducted 
to identify modelling approaches assessing the cost-effectiveness of HIV treatments. 
Additionally, the use of DES models within Health Technology Assessments (HTA) 
was evaluated. A de novo DES was developed in Microsoft Excel® with VBA, based 
on assumptions and data from an existing cost-effectiveness Markov model assess-
ing HIV treatments. Results: Of the HIV publications identified, 4% used a DES 
and 42% used a Markov model. Only 17% provided a discussion around their choice 
of model type. DES models have not yet been used in HTAs for HIV in the UK but 
nine were identified within other disease areas. The de novo DES and those in the 
published literature demonstrated a realistic modelling approach due to the dis-
crete timing of events and accounting for patient heterogeneity. The DES is a flex-
ible model which can accommodate future adaptations; however, it relies heavily 
on data requirements in order to maximise its potential benefit. ConClusions: 
Neither Markov models nor DES are superior; the key is to choose the most suit-
able model for the decision problem and provide a clear rationale. In the context of 
HIV, DES is likely to be a good choice of model providing sufficient data is available.
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oPtIMIzIng PRefeRRed outcoMes
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objeCtives: We demonstrate an approach to select evidence-based preventive treat-
ment thresholds by optimizing preferred outcomes illustrated with a study on preven-
tive statin treatment based on 10-year coronary heart disease (CHD) risk predicted 
by the Framingham risk score (FRS). Methods: A Markov decision-analytic model 
was used to simulate cohorts following usual care; preventive statin treatment in 
high-risk (FRS≥ 20%) individuals (ATPIII guideline), or, alternatively, an explorative 
approach of lowering treatment threshold T from 20.0% to 0.0% with 0.5% decre-
ments. A population-based cohort (n= 11,649) was used to recalibrate the FRS and 
calculate the distribution of individuals over the low (< 0.5T%), intermediate (0.5T%-
T%), and high (≥ T%) risk category and corresponding observed CHD risks. Treatment 
complications, quality-adjusted life-years (QALYs), and Net Health Benefit (NHB) 
(willingness-to-pay of $50,000/QALY) were evaluated. Uncertainty was assessed 
through probabilistic sensitivity analysis. Furthermore, we assessed the balance 
between additional individuals treated and additional health benefits when incre-
mentally lowering the threshold. Results: Over a 30-year time horizon, QALYs in 
men ranged from 12.679 at T= 20.0% to 12.752 at T= 0.0%, with a maximum of 12.753 
at T= 1.5%. For women QALYs ranged from 13.474 at T= 20.0% to 13.587 at T= 0.0%, with 
a maximum of 13.589 at T= 1.5%. Lowering the threshold monotonically increased 
costs, whereas the incremental NHB was favorable for every T< 20%. Incrementally 
lowering the threshold and comparing outcomes to the former threshold, for men and 
women marginal health effects achieved a maximum at T= 10.0%, whereas marginal 
costs were highest at T= 1.0% for men and T= 2.5% for women. The marginal NHB was 
favorable down to T= 2.0% for men and T= 3.5% for women. ConClusions: Risk-
stratified prevention is increasingly recommended, while current intuition-based 
treatment threshold selection leaves ample room for health gain and cost-savings. 
Evidence-based selection, including estimation of long-term (marginal) health effects 
and costs, is essential, whether the goal is to maximize health outcomes or optimize 
cost-effectiveness.
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ModelIng tReatMent sequences In health technology assessMents
Zheng Y, Pan F, Sorensen S
Evidera, Bethesda, MD, USA
objeCtives: As interventions available in a therapeutic area increase, the relevant 
decision question in health technology assessment (HTA) expands to include iden-
tifying the optimal treatment sequences or position for a treatment in a sequence. 
This study reviewed economic models capturing treatment sequences published 
by National Institute for Health and Care Excellence (NICE). Methods: Economic 
models including a treatment sequence assessed by NICE were reviewed as these 
HTAs generally provide comprehensive detail on modeling. The rationale for 
modeling a sequence, modeling technique used, and approach to characterizing 
clinical, cost and utility impacts were evaluated. Results: Forty models were 
identified that considered treatment sequences in the following therapeutic areas: 
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objeCtives: The ongoing ASCEND trial of natalizumab utilizes a novel composite 
endpoint, comprised of the Expanded Disability Status Scale (EDSS), Timed 25-Foot 
Walk (T25FW) and 9-Hole Peg Test (9HPT) to assess disability progression in patients 
with secondary-progressive multiple sclerosis (SPMS), due to the limited ability of 
EDSS alone to assess disability progression in this patient population. Given that 
the ASCEND data are not available, data from the IMPACT study was used to assess 
the cost-effectiveness of SPMS treatments in an economic model capturing the 
interrelated changes of these measures for individual patients. This study presents 
the model concept and assesses its external predictability. Methods: A discrete 
event simulation was developed to predict times to disability progressions on EDSS, 
T25FW, and 9HPTand the occurrence of relapses over time, using four parametric 
(Weibull) functions, each adjusted by a Cox model to ensure that each event time 
was estimated based on patients’ baseline and time-varying factors. Each disability 
scale’s value is updated as events occur. Data from the IMPACT study (n= 436, fol-
lowed for 2 years) was extrapolated for longer term. Published data on EDSS from the 
University of British Columbia (UBC) MS database were used for long-term external 
validations. Results: The model closely replicated all four endpoints as observed 
in the IMPACT study at two years. The predicted times for 25% of patients to reach 
EDSS 8 were consistent with those from the UBC data, with 13.4 (model) vs. 14.8 
(UBC) years from EDSS 3.5–4.5, and 8.7 vs. 8.6 years from EDSS 6.0. The distributions 
of T25FW and 9HPT by EDSS level predicted at 10 years were consistent with those 
observed from the IMPACT study. ConClusions: This SPMS model reliably pre-
dicts short- and long-term disability levels, and can serve as the basis for economic 
evaluations of treatments for SPMS.
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IMPleMentatIon of PoPulatIon dynaMIcs In ModellIng health 
and Budget IMPact of an InteRventIon foR a chRonIc dIsease WIth 
MultIPle dIsease suBtyPes
Tran-Duy A1, Boonen A1, Caro JJ2, Severens JL3
1Maastricht University Medical Center+, Maastricht, The Netherlands, 2Evidera, Lexington, MA, 
USA, 3Erasmus University Rotterdam, Rotterdam, The Netherlands
objeCtives: In a budget impact analysis (BIA), the population is supposed to 
include all patients eligible for the new intervention during the time span of deci-
sion: new incident cases and patients leaving due to death, cure, migration or other 
reasons, must be captured. Additionally, temporal changes in the actual number of 
individuals receiving the intervention must be quantified. While most of the guide-
lines for BIA emphasize this population dynamics aspect, recommendations on how 
to technically implement it are lacking. We introduce a method for implementing 
population dynamics in a chronic disease with multiple disease subtypes using 
object-oriented programming (OOP), and demonstrate its application in model-
ling health and budget impact of a treatment strategy for ankylosing spondylitis 
(AS). Methods: A generic hierarchical patient class structure was developed to 
systematically organize the prevalent population and incident cohorts of patients 
with different disease subtypes. Using the concepts of inheritance and polymor-
phism in OOP, we formulated algorithms to efficiently compute health measures 
and resource utilization of individual patients in different classes, and to perform 
probabilistic sensitivity analysis. In the case study, a dynamic population model was 
developed to predict the burden of AS in the Dutch society over a 20-year period from 
January 1, 2015 onwards when a sequential treatment strategy including tumour 
necrosis factor antagonists was applied. Data for model parameterization were 
obtained from the Outcomes Assessment of AS International Study (OASIS) and 
literature. Results: The case study demonstrated that our dynamic population 
modelling method offers an efficient approach to quantify annual as well as total 
health and costs for different decision time spans. Annual direct costs incurred 
by the AS patients in the Dutch Society would range from 471 to 496 million Euros 
between 2015-2035. ConClusions: Our method for implementation of population 
dynamics is efficient and generic, so it can be applied to other chronic diseases.
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Budget IMPact analysIs of delayed-Release dIMethylfuMaRate In 
the tReatMent of RelaPsIng-ReMIttIng MultIPle scleRosIs In Italy
Furneri G1, Marchesi C2, Santoni L3
1EBMA Consulting, Melegnano, Italy, 2Biogen Spa, Milan, Italy, 3Biogen, Milan, Italy
objeCtives: To evaluate the economic impact of a recently approved therapy, 
delayed-release dimethylfumarate (DMF; also known as gastro-resistant DMF), on 
the overall management costs of relapsing-remitting multiple sclerosis (RRMS) in 
Italy. Methods: A budget impact model, adopting the perspective of the Italian 
National Healthcare Service (NHS), was used to compare healthcare costs of two 
different treatment scenarios: a) base-case, in which DMF is not reimbursed/funded 
by the NHS, vs. b) reimbursement-case, in which DMF is reimbursed and funded by 
the NHS. Healthcare costs sustained by the Italian NHS to manage the RRMS popu-
lation (drug treatment, administration, therapy and disease monitoring, relapse 
management, treatment-related adverse events) have been calculated over 3 years 
and compared for the two scenarios. Impact of relapses for the disease modify-
ing therapies (DMTs) included in the analysis was estimated using results from 
published literature. RRMS population treated with DMTs was estimated using 
Italian prevalence and incidence data. According to these estimates, the number 
of treated patients amounted to 35,100 at Year 1, 36,800 at Year 2, and 38,700 at Year 
3. Results: According to current price and reimbursement conditions established 
by the Italian NHS, it was estimated that the introduction of DMF (reimbursement-
case) would determine a decrease of the budget impact, if compared with the 
base-case (non-reimbursement case). Over three years, the budget impact would 
be € 1,388,640,000 in the base-case and € 1,359,800,000 in the reimbursement-case 
(-€ 28,840,000; -2.1% relative budget variation). The main drivers for cost-saving were 
pharmacological treatment costs and reduced burden of relapses (corresponding 
to about 1,500 avoided relapses). ConClusions: At the current reimbursement 
increased risk of secondhand smoking on morbidity and mortality. The impact of 
secondhand smoking was included in a previously published Markov model called the 
BENESCO model to estimate the economic burden in Korea. Transition probabilities 
and costs were acquired from Korean public data. The time horizon was lifetime and 
assumed 5% discount rate for costs. The estimated cost was compared with published 
estimates to establish external validity of the model. Results: 13.7% of women (≥ 
19 years old) and 30.7% of children (13-18 years old) from general population were 
exposed to secondhand smoke in household. Relative risks of secondhand smoking 
related diseases were lung cancer 1.9(95% CI 1.0-3.5), coronary heart disease 1.27(95% 
CI: 1.19-1.36), stroke 1.25(95% CI: 1.12-1.38) in women married for smoking husbands. 
The odd of Asthma onset was 1.32 times higher in children whose father smokes. The 
estimated costs were increased by 10 to 50%, compared with the model without the 
impact of secondhand smoking. ConClusions: Cigarette smoking and exposure 
to secondhand smoke is associated with significant economic burden. Policymakers 
should be advised that tobacco control should be aimed not just smokers, but those 
who are vulnerable to secondhand smoking, especially women and children lived 
with smokers.
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InvestIgatIng the IMPact of conteMPoRaRy RIsk factoRs foR 
dIaBetes coMPlIcatIons and theIR evolutIon on RIsk PRedIctIon 
usIng the ukPds 82 equatIons
McEwan P1, Foos V2, Lamotte M3
1Health Economics and Outcomes Research Ltd, Monmouth, UK, 2IMS Health, Basel, Switzerland, 
3IMS Health, Vilvoorde, Belgium
objeCtives: UKPDS 82 provided updated and new event equations for use in type 
2 diabetes mellitus (T2DM) that include new risk factor (RF) predictors. These new 
RFs do not routinely get reported in clinical studies; consequently, the objective 
of this study research was to report plausible baseline RF values and their time-
dependent trajectories and quantify their impact upon predicted complication 
rates. Methods: Availability of baseline and time-dependent RF data was assessed 
using a pragmatic literature review. Univariate sensitivity analysis of the UKPDS 82 
equations (over a 40-year horizon ) was undertaken to assess the impact of low-
density lipoprotein [LDL]; microalbuminuria (MA); heart rate (HR); white blood cell 
count (WBC): haemoglobin (Hb) and estimated glomerular filtration rate (eGFR) on 
predicted diabetes complications per 1,000 patients, using UKPDS baseline values 
(varied within the 95% central range). Results: The review identified 32 studies 
reporting baseline RF values typically consistent with UKPDS (review versus UKPDS): 
LDL (2.6-3.8 versus 3.49mmol/l); MA (11-45% versus 6.5%); HR (67-72 versus 72bpm); 
WBC (5.7-7.9 versus 6.6x106/ml); Hb (12.4-14 versus 14.5g/dl); the exception was 
eGFR where baseline values (33-101 versus 77.5ml/min/1.73m2) and decline (0.3-
5.2ml/min/1.73m2/year) varied widely. Utilising UKPDS 82 baseline values resulted 
in 877 macrovascular and 133 microvascular events predicted with 691 to 1,181 and 
116 to 182, respectively, predicted in sensitivity analyses; drivers of risk were LDL 
and eGFR. Varying eGFR decline between 0.3 to 5.2ml/min/1.73m2/year resulted 
in annual event rates for end stage renal disease (ESRD) between 0.021 to 1.251%; 
holding eGFR constant over time resulted in ESRD annual event rate of 0.020%, 
significantly lower than observed in UKPDS (0.13%). ConClusions: Appropriate 
specification of RF is important in diabetes modelling. This study suggests that 
the UKPDS profile is generally consistent with other identified T2DM populations. 
Modelling a decline in eGFR improved the predictive accuracy of ESRD incidence.
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BetteR ReIMBuRseMent decIsIon-MakIng Based on exPected cost-
effectIveness: usIng value of InfoRMatIon decIsIon analysIs to 
IMPRove the desIgn and effIcacy of a Phase III PRogRaM foR eRlotInIB
Mukherjee SC1, Latimer N2, Richards P2, Nixon RM3, Hall PS4
1Pharmerit International, York, UK, 2University of Sheffield, Sheffield, UK, 3Novartis Pharma AG, 
Basel, Switzerland, 4University of Edinburgh, Edinburgh, UK
objeCtives: Erlotinib, a tyrosine-kinase inhibitor, has been recommended for use in 
non-small cell lung cancer patients harbouring an EGFR mutation. The present study 
is retrospective in nature; using published clinical trial data for erlotinib, it demon-
strates how an analysis of Phase II data could be used to identify what data Phase III 
studies should focus on collecting. Methods: Phase II data were identified through 
a targeted literature search and used to determine the cost-effectiveness of erlotinib, 
utilising a simple Markov model framework. Data from the literature were mapped 
to model inputs using statistical data analysis methods. Value of Information (VOI) 
analysis tools, such as Expected Value of Perfect Information (EVPI) and Expected 
Value of Partial Perfect Information (EVPPI) were used to identify those uncertain 
parameters having research value in a prospective Phase III program. These findings 
helped to optimise the design of a hypothetical Phase III trial for erlotinib that could 
collect data that is most relevant for reimbursement decision-making. Results: 
At a cost-effectiveness threshold of £30,000 per quality-adjusted life year (QALY) 
gained, the population EVPI was £3,269,358, indicating that further research is valu-
able. The EVPPI identified the log hazards of erlotinib (intervention) and gefitinib 
(comparator) for progression-free survival and overall survival as the parameters for 
which uncertainty was the most valuable. The value of the uncertainty associated 
with other parameters, such as utilities and costs, was much lower. Hence, subse-
quent studies should focus on providing further information on efficacy parameters 
rather than on utilities and costs. ConClusions: Undertaking VOI analysis on data 
collected at Phase II can help ensure that Phase III trials are designed efficiently, in 
turn ensuring that uncertainty in future decision-making is minimised. This model 
demonstrated the VOI from a public policy perspective. This could be extended to 
other perspectives to ensure greater relevance in different settings.
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